Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The SEC Cracks Down On The Biggest Market Threat: Short Sellers On Twitter
http://www.zerohedge.com/news/2015-11-11/sec-cracks-down-biggest-market-threat-short-sellers-twitter
Maybee they need to get a hint ... or two of it.
Have sold 10 % yesterday - needed the cash for something else.
The rest stays here - when funds are back i am adding again.
Thank you so much for this post Bernadc!
This quote from Dr. Macfarlane underlines the strength from Anavex again.
Trading Volume in germany is now:
Frankfurt: 6381 shares
Stuttgart: 10750 shares
Premarket volume in US-market is 912 000 shares around and rising.
Do you have even a clue how much shares are traded here?
As i am watching the trades here in germany and how much % is it from the whole pre-market trading - u know?
I doubt it.
And what exactly have 3 marketplaces in Germany to do with naked shorting?
And how about marketplaces in France, Netherlands, UK, Spain, Italy and so on?
Excellent summary.
Thank you very much.
About this point i am thinking the whole day!
For new investors in biotech and also for the experienced to refresh their knowledge here a good read.
http://www.biotechpicklist.com/bioinvesting/
Point 1,4,12,13,16 .... well in the end all points are worth reading it.
Tell a father here how "great" that day was:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118357375
Proud of it?
Great post.
My sincere condolences. I am deeply sorry for your loss.
Im happy that Cramer bashes AVXL, cause:
So i know i have something really good here.
If he would recommend Anavex i would be scared about the future of the company.
Meanwhile i use Cramer as perfect contra-indicator for a long time.
For example when u go to www.finviz.com + put in the stock of your choice and take a quick look at the news (below the chart) and see Cramer is pushing this stock more than 2 times - beware of it.
It was several times i skipped to invest in a company - just because i saw him pushing that one.
So now he confirms my good choice with Anavex.
Here is a good summary:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118346238
And the winner is: not AXON
Here you go if u want the real deal:
Positive Safety Data, Statistically Significant Improvements on Exploratory Clinical Endpoints
NEW YORK, NY, November 9, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL). On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.
Initial analysis of Phase 2a data demonstrated that the study met the primary objective of safety as ANAVEX 2-73 was well tolerated and results were consistent with prior Phase 1 clinical trial data. The secondary objectives were also met, with ANAVEX 2-73 showing cognitive improvement across all doses in all exploratory cognitive measurements, including the Cogstate battery, Mini Mental State Examination (MMSE), event-related potentials (ERP) and P300 tests, which consistently demonstrated improvements from baseline in the completed PART A portion of the study in 32 mild-to-moderate Alzheimer’s patients. Even though PART A was designed as a 5 week bioavailability trial that included a built-in wash-out period of 12 days and without an optimized dosing regimen, several Cogstate tests demonstrated highly statistically significant improvements. This finding was supported by a trend towards improvement in median MMSE score, which increased by +1.5 over baseline at week 5.
Positive effects on cognition were further supported by highly statistically significant biomarker effects of treatment at week 5 on one event-related potential (ERP) measure with a p-value of p<0.0007 and improvement in the P300 signal. The ERP biomarker scores improved compared to the initial data presented at AAIC in Washington, DC in July 2015, by which time not all patients had yet completed PART A.
All patients who completed PART A volunteered to continue in the longitudinal PART B extension study.
In the interim analysis of the first 14 patients at week 12, the PART B portion of the study demonstrated a positive trend towards improvement over 12 weeks of ANAVEX 2-73 treatment on the secondary functional outcome measure, the Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory (ADCS-ADL) by +3.21 points.
“While it is of prime importance to have confirmed that both the primary and secondary endpoints of the trial have been met, it is extremely encouraging to see the emergence of such strong cognitive signals after only 5 weeks of treatment. Such an outcome in a trial such as this is unprecedented in my experience, and the current results suggest that ANAVEX 2-73 could potentially make a significant difference in patients’ lives,” said Associate Professor Stephen Macfarlane, FRANZCP, Director of Aged Psychiatry at Alfred Health, who conducted the study. “We continue to receive extremely positive feedback about the effects of the drug from our study participants and their caregivers. The results justify a prospective comparison with current standard of care in a larger clinical trial.”
Professor Paul Maruff, Chief Scientific Officer of Cogstate commented: “The Cogstate tests measure people’s ability to store and use information. The results of the Phase 2a study demonstrate that ANAVEX 2-73 improves psychomotor function, attention and working memory. For attention and working memory these improvements were statistically significant with a p-value of p<0.05 and p<0.001, respectively and their magnitude clinically important. To my knowledge, we have not yet seen a drug that has improved quantitatively working memory to such an extent as seen with ANAVEX 2-73”.
Professor Harald Hampel, member of Anavex’s Scientific Advisory Board, and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC) in Paris, France, commented: “The collective data from this Phase 2a trial supports the concept of targeting the sigma-1 receptor with ANAVEX 2-73 with a degree of confidence that we did not foresee. Sigma-1 receptor presents an innovative interventional upstream approach to impact key cellular events believed to contribute to Alzheimer’s disease pathophysiology. The presented Phase 2a data underlines the importance of rigorously investigating a potential efficacy signal on co-primary outcomes such as cognition and function in larger and well-powered trials”.
“We are encouraged by the preliminary safety and efficacy data. We look forward to continuing with PART B of the Phase 2a trial and expect to provide data updates at 12 week, 26 week, 38 week and 52 week time points,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “While we remain focused on Alzheimer’s, the remarkably fast onset of clinical effect of ANAVEX 2-73 increases our options to potentially pursue additional indications for diseases characterized by working memory impairment and may enable clinical trials to be completed within shorter time frames.”
The presentation entitled “New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients” was presented by Professor Steve Macfarlane at CTAD in a late-breaking oral session and is available on the publications page of the Anavex website.
About the ANAVEX 2-73 Phase 2a Study
32 subjects who met NINCDS-ADRDA criteria for probable AD were recruited at five clinical sites in Melbourne, Australia. Subjects are between 55 and 85 years of age, and have a MMSE of 16 to 28. In PART A of the study, participants were administered ANAVEX 2-73 orally and IV in a randomized, open-label, 2-period, cross-over trial separated by a wash-out with adaptive study design lasting up to 36 days (5 weeks) for each participant. In PART B of the study, all participants are administered ANAVEX 2-73 daily orally.
At week 5 the MMSE score increased by +1.5 over baseline. The Cogstate Identification Task, Cogstate One Back Task and ERP Reaction Time all showed statistically significant improvements. In a preliminary interim readout of PART B data, ANAVEX 2-73 improved ADCS-ADL score, a functional measurement, over a period of 12 weeks by +3.21 over baseline, with 11 out of 14 (78.6%) patients improving. Both MMSE and ADCS-ADL are regulatory approved endpoints for pivotal Alzheimer’s disease trials.
The ongoing, multicenter Phase 2a adaptive trial of ANAVEX 2-73 in both male and female mild-to-moderate Alzheimer’s patients enrolled 32 participants. It commenced in January 2015 and the participants, the majority of whom are also taking donepezil, have now completed PART A of the two-part trial. Lasting up to 36 days (5 weeks) for each patient, PART A was a simple randomized, open-label, two-period trial with an on-off-on not-yet-optimized dosing regimen to assess bioavailability, and cross-over between oral (30mg/50mg) and IV (3mg/5mg) administration. Event-related potentials (ERP) were used to assess cognitive effects and optimize dosing of ANAVEX 2-73. PART B is an open-label extension for a further 52 weeks. Initially planned for 26 weeks, PART B was extended to 52 weeks as a result of requests from patients and caregivers. PART B utilizes daily oral dosing in order to establish a longer drug effect.
The primary endpoint of the Phase 2a trial is evaluation of safety and tolerability of ANAVEX 2-73, which had shown potential in preclinical studies to prevent, halt and/or reverse the course of the disease. Secondary endpoints were dose response, bioavailability, and exploratory cognitive effects using electroencephalographic (EEG) activity and event-related potentials (ERP), Cogstate battery, Mini Mental State Examination (MMSE), and evaluation of Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory (ADSC-ADL) as well as the exploration of ANAVEX 2-73 as a potential add-on therapy to donepezil, the current standard of care. The combination of ANAVEX 2-73 and donepezil (Aricept®) is known as ANAVEX PLUS.
Additional information regarding the trial is available from the U.S. National Institutes of Health (NIH) clinical trials database at www.clinicaltrials.gov.
http://www.anavex.com/?news=anavex-announces-positive-primary-and-secondary-endpoints-were-achieved-in-a-phase-2a-clinical-trial-of-anavex-2-73-in-alzheimers-disease
Excellent PR - top scientists praising Anavex is a homerun.
For your information:
The volume is sharply increasing in Germany right now together with the shareprice raising fast too.
I love the smell of fried shorties in the morning.....
Good summary - thank you.
There is a phrase: Birds of a feather flock together.
Time to short AXON - they failed again at CTAD.
*Anavex is far more promising - just look at the results in the PR at Monday.
Taking revenge on Shkreli?
Someone claimed that this dude is a buddy fom Ax*on´s Ceo.
As Ax*on could not deliver good results at CTAD but Anavex did maybee he wants to protect that other company with attacking Anavex.
Also Jim Cramer was pushing Ax*on:
http://www.thestreet.com/story/13146740/1/jim-cramers-top-takeaways-axovant-sciences-amerisourcebergen-isis-pharmaceuticals.html?puc=yahoo&cm_ven=YAHOO
How will Shkreli and other shorters feel if there are popping up hundreds of short recommendations and bash-postings at the boards of the company he is connected to?
And really: If u compare the market capitalisations from both companies:
Ax*on 100 mil shares to 16 Dollar
Avxl 35 mil shares to 8 Dollar (rounded)
And Anavex is delivering far better results then u know which one is a pump and dump and which one is the real deal.
And i believe that the smart money will see this in the same way - so i expect a rise in pps at AVXL.
For every invested Dollar in AVXL u get 5 times bigger percentage of the company as it will be at Ax*on.
As Wallstreet hates uncertainty - this will be gone after the PR at Monday and the buying begins.
If all the noise at Anavex which the shortsellers createted will be enough to distract the investors from the bad situation at Ax*on for longer time - i doubt it.
Harald Hampel - Member of advisory board:
Here is a Youtube video where he introduces himself and explains a lot about his research in AD.
Uff - what a week.
Still have all my shares and looking for results from CTAD and a PR to get an image of the future progress in 2016.
After the presentation and Monday the picture will be clearer.
There is no AH for europeans like me so:
Rien ne vas plus...
Wohoo - good catch, Alinea818!
Dr. Missling is already working on the partnership.
He says what he thinks and he does what he says - i love it.
Who knows - maybee first talks have taken place long before the CTAD-Conference and those just want to see the results there before the final talks happens.
This Ceo has so often bring a positive surprise, that i would not wonder if there will come more - hopefully while some shorts having their pants down.
Thank you very much for this summary/explanation.
The issue about the meaning of "average" at the abstract should be cleared now.
Maybee thats why they "work" so hard now to get the pps down after hours to trigger more margin calls tomorrow right at the opening?
And it is their last shot to do so.....
Good catch, Imho.
He will have some extry juicy details to present there, which is not contained in the abstract now.
We just have to wait.
He can give a hint with the abstract - and he did so - but he cant pack all results there into.
The essential point i was looking for is the confirmation of the promising first results from august - and i got that already from the abstract.
The final results can improve my faith to this company but the minimum is already reached and surpassed.
So i dont see any reason to sell - even if the shorts are creating panic and dumping in AH and (this is the worst:) trigger margin calls.
For those who are forced to sell i feel really sorry.
Normally this should be investigated by the SEC.
They are going to use all "their skills" to get the retailers out of this but they wont have success at all of them.
Anavex stops and reverses Alzheimer and improves the MMSE score.
That is what we are looking for - the Ceo clearly communicates this. (as much as he can - cause restricted til presentation is done)
So you can trust a Ceo which has proven to be honest and also is able to be successful + his top notch advisory board - where most members have 20+ years experience in this science or u keep following those "experts" which predicts doom and spread chaos.
I have choosen and stick to the first way - 2 days artificial chaos cant reverse this as nothing fundamental has changed.
And tomorrow may be an other day where the ups and downs may be irrational but at the end counts how much shares u have when the friday is done.
AH is fast climbing from the lows - atm back to 10,40.
The low has been at 9,04.
Yes he is.
I agree with you - thank you Bernadc.
Noise, noise, ..lots of noise...
Thats where the shorties are good for + good entries for adding up to your stake.
I am not worried at all, cause:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118255583
Time is running out - tic toc
I agree with your observation - i have noticed that too.
Also i suspect the shorts are send here from the same ones who are buying, to get the pps down again as it raised to fast and to stop the retailers from accumulating more, which means less cheap shares for them.
Small sells - 100 shares again and again and then a 10 000 buy - i saw that often.
Dont forget - our float is not really big.
Thank you for confirming this, Jimmy.
The shareprice is just valid now for the next 2 days.
Monday will be the day where the market re-evaluate the shareprice of Anavex.
If the market thinks the Anavex is at least as valuable as AXON is, then we will gap up + run up during monday to 50 Dollar.
And it does not matter whether the pps of anavex is friday at 5 or 15 or 35 dollar - it will just go up to 50 or higher, if the market valuates it so.
So the noise from the shorters ist just ... noise... nothing else. They wanna scare you out of the shares - thats all.
Only one thing is important - hold your shares!
The pps of the next 2 days is relevant only for exactly these 2 days!
The chart dont matters anymore.
The only thing which matters is: You are in or you are out before the closing bell at friday.
If it double tomorrow or it wents down the half - i will still have all my shares and monday will be the day where the valuation will be made for these shares - i expect a gap up and it will be not a small one!
Missling is already ahead of all of us.
I dont post that often but after some exiting days and in front of more exiting days to come i want to share some thoughts here.
As the Barcelona conference is close i tried to put myself into the position of Dr. Missling. - and i did it with a comparison of an auction at Sotheby´s.
As i have to admit i never have taken part at such an auction though i might have an imagination how it works.
Now imagine urself there is a unique Diamond with 100 % clarity and so much carat that he is the top of all exceptional offers at that day there.
And all the interested parties may have a look at it in the showroom before the auction begins. And all will have that look and afterwards they want it.
And they may also have a very nervous look at their comeptitors as they are ALL there, lurking each other as their view is also on that beauty.
That is the situation in Barcelona.
The moment when Anavex shows the results - backed up by the scientists from his advisory team, which are really the top of the top - and all of them - then he shows what he offers.
All of the BP will be there and Dr. Missling is clearly communicating that he wants a partnership and only one of them will get it.
His position for negotiating he strengthened already with the financial deal with LPC before - so he is not in the need anymore to accept some shabby offer.
BP knows that too - the filing is out and open to read for anyone.
So they will suspicious observe each other while he can wait for the offers to come and i am very confident that he will only accept a deal which is very sweet!
Barcelona is like the showroom with the bonus that all competent bidders are there together.
This is an amazing Ceo.
He communicates clearly!
He executes his plan step by step - remember the uplisting:
The ratio for the resplit was really low - just enough to get uplisted + overcome the 5 Dollar pps restriction for the institutional holders.
And he did it fast and very successful.
In my opinion it is not the question whether he will partner up - its just the question WHEN he will do it!
And that might come faster than some suggest.
I expect that talks start immediatly after the results are shown there at the weekend.
This is the biggest market ever for BP and they know it.
A global disease, where the drug attracts also global players like Bayer from Germany and so on.
And the market grows year for year - as it is not a cure in my opninion.
It is more like Insulin for a diabetic. You have to take it for the rest of your life - then u are fine. Therefore the revenue is much higher than a 1 time drug which cures in 3 weeks something.
One more information about the tradingplaces here in Germany.
Meanwhile we can buy AVXL-shares direct at the US-marketplace. The spread is much lower there, so most of us choose this way.
If u see low volumes in Frankfurt and Stuttgart - dont think there is no interest. The uplisting opened the possibility of direct-buy at the US-stock exhange too and that is much more used now.
I am holding all my shares with much confidence and the noise from the shorts cannot distract me from my longterm view as they try to focus the people to the shortterm movements instead holding to their initial plan.
Some smart people here mentioned it before: KNOW WHAT YOU OWN!
Thank you for your time reading this and greetings from europe
At the end of last week Stuttgart began to trade AVXLD.
Before it was only Berlin, which is not a big or lets say important marketplace here - Stuttgart and Frankfurt are the important ones.
Frankfurt and Munich i expect to follow soon and i smiled as i saw one of them already started with AVXLD before uplisting is final.
When there was the Octoberinvest in NY and i read that Dr.Missling has invited there and that way is connecting US and Europe - i was not surprised - he clearly thinks globally for Anavex - not only in regards for the investment but dont forget: this disease is a globally disease.
Additional he is personally involved with AD as it has appeared in his family.
Also keep in mind that if the FDA thinks it needs to delay the whole process for some reasons he has a second opportunity to get access to the drug-market over Europe.
I would not wonder a single bit when Dr. Missling will present one day Anavex at the real Oktoberfest here in germany in Munich, where all the mighty and rich comes together to meet and connect. Politics and Industrie - all will be there and he showed already that he is capable to do it - in a smaller way in NY - and next time in Munich?
It is just a guess but....he is a smart Ceo which surprises us positive again and again.
WOUW ... Truely a masterpiece of post!
I did read the article today in Seeking Alpha and felt a bit offended by the author as he described the "Longs" like me as some sort of sheeps following a "CULT-stock".
Thanks to a lot of knowledge which i could get from here and other sources it couldnt really bother me at all.
Your analysis is one of the best i have read and i will continue to translate all informations i can get to my friends here, which are also invested in Anavex.
Greetings from Europe
P.S.:
Here in Germany a second marketplace in Stuttgart had opened since a few days - though not much trades up to now.
I expect the others following as soon as the uplisting is fully done.
My opinion is that after uplisting more places will open and and after the news from CTAD the volume will increase enormous.
If and how the changes in other euopean countries are - i cannot answer as i just dont know.
I have been waiting for this:
Back in August this year i was mentioning in my first post here that we miss a lot of buying pressure at this stock:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116476200
All the time i was waiting to reach 3 Dollars to get uplisted and then reach 5 Dollars for the second key-point.
Too much guys with deep pockets have restrictions to buy Anavex cause:
1. no OTC allowed
2. no stock below a pps of 5 Dollars allowed.
3. both of them
Now this Ceo has catched both flies with 1 strike as we got uplisting and are above 5 Dollars.
Also do not forget the additional european marketplaces will also add Anavex now! ( as described in my previous post)
So we will get this additional (former missing) buying pressure.
The last 2 green candles (before today) was mostly driven by retail and a few institutional investors, which had no such restrictions - just driven on the good news of the coming conference in Barcelona.
And now imagine what would have happened to the pps in the last 2 days, if all those guys with deep pockets would have been able to buy too? - they got the Barcelona news too!
Now they can.
So let the fireworks begin......
One last remark - i have 2 other stocks, that i really like - but in case the pps will tank more...... i have already pre-defined 2 sell orders and pre-defined a buy order for Anavex.
So shortie .... go - make my day!
Anavex is not just a pill against AD.
It will be much more.
For those who compare Anavex with one of the backstreet pill-shops, which exist a lot in the OTC - i say:
Go to the Anavex Homepage and read the data sheets of every single member of the leadership.
http://www.anavex.com/about-us/leadership/
They are building up something much bigger - a basement for a great company with multiple assets in their pipeline already.
It is clearly not their goal to archive one fast success and sell the whole thing to the first bidder.
I will give u an example - here it is regarding the Patents:
Source: http://www.anavex.com/?news=anavex-strengthens-board-of-directors-2
The extract of it:
Anavex Strengthens Board of Directors
NEW YORK, NY – June 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Steffen Thomas, PhD, to its Board of Directors. Dr. Thomas has 15 years of experience in intellectual property, patent law and proprietary technology rights as well as significant expertise in small molecule pharmaceuticals.
Dr. Thomas is currently a patent attorney, European patent attorney and European trademark attorney at Epping Hermann Fischer, a major European intellectual property law firm. Previously, he worked for Japan-based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he worked for Nycomed Pharma, which was acquired by Takeda in 2011 for approximately USD $10 billion.
Dr. Thomas’ legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing opinions on patentability and infringement in the technical field of chemistry.
“We are pleased to welcome Dr. Thomas to our Board,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We believe Dr. Thomas’ expertise in intellectual property as well as his pharmaceutical industry insight will be extremely beneficial as we are advancing our pipeline.”
What i mean is:
You dont get an Patent-expert onboard if u are going just for 1 single Patent - you will get him when u build up something where u need him again and again - as there is much more than just Anavex 2-73.
One more snippit that fits in the bigger picture comes from this source here:
http://www.anavex.com/?news=anavex-strengthens-alzheimers-pipeline-obtains-exclusive-worldwide-rights-to-intellectual-property
"Obtaining exclusive worldwide rights to this intellectual property is exciting as it is another step in Anavex’s overall strategy to build a broad and leading platform of technology and intellectual property for the development of mixed muscarinic and sigma-1 therapeutics. It also adds to our already dominant position in this field,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex."
Read all the data from the leadership of all members and u see clearly that Anavex has the top of the top of Science and advisors onboard. Here arises a company with high valuable assets and the Ceo really cares about securing the properties.
And also the other members there are very impressive too as:
"Dr. Fisher is co-founding Chairman and President of the Alzheimer’s and Parkinson’s Diseases Conference,is on the scientific review board of the Alzheimer’s Drug Discovery Foundation and is a reviewer of the Alzheimer’s Association."
or
"A member of the Scientific Advisory Board, Dr. Harrison is an internationally acknowledged specialist for design of human clinical outcome measurement in Alzheimer’s disease and other cognitive impairments. Dr. Harrison has successfully integrated cognitive testing into drug development programs for many pharmaceutical and biotechnology companies including eight of the current ‘Fortune’ top 10 pharmaceutical companies."
And so on- there are so much more examples which i could list here.
After studying the leadership i knew, that this is an international top team, which sends a clear signal that they were going for the bigger picture, which gave me much confidence.
The actual listing at the OTC dont really matters me as it it just a question of time when (not if!) the uplisting will be.
So please take the time and do your homework and read all about the company and who runs it - that may answer more questions as to read the pps is up 2 cents or down 3 cents .... and it may also help to differentiate the good from the bad on OTC by doing so - that is called DD.
One last remark for those who are seeking an entry point here in this stock:
An excellent post from Bernadc (tyvm for it) - not much words but sooooo powerful:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116828225
Thank you for your time reading this and good luck in all your investments.
This is some very fine example of explanation - thank you very much.
Though i do know all around the free-float already i really enjoyed to read this - also for novice investors it will bring new knowledge.
My shares are as well not part of the real float anymore - same with those of my friends.
I appreciate your comments here and on Yahoo as you rationalize your conclusions and assumptions very well.
85 000 shares at Berlin in 1 trade today:
I was really astonished to see such high trade at Berlin today 5 hours before US-market opens - for 1,49 Euro each.
There in Berlin seems to be a single trader which offers these OTC-stocks on his own risk and profit and he does that not every day.
I remember while i was raising my stack in Anavex in the last weeks, that i had sometimes to wait 2 days till he was willing to trade again and give me the wanted shares - or i needed to phone him again.
And all the time i need to pay like 10-20 % more than in comparison to the US-price.
Though Berlin is our capital it is a small and unimportant marketplace in stock trading.
Frankfurt and Stuttgart are the main places here - that means not much people in Germany are able to buy AVXL-shares.
For further information+description of the problem to get AVXL shares pls read my initial post (numer 15519) in this board here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116476200
One last remark: Someone who is willing to pay 10-20 % over market for the shares is really to be seen as longterm investor for sure - like me.
Thank you very much for all the kind responses.
I am from Germany and my Broker is Cortal Consors and i have to admit that i am very pleased with him.
I have understood the restriction in that way, that the US-broker which works together with Cortal is the one which will not trade the so called "penny-stocks" anymore - everything below 3 Dollar is such.
The Ceo Dr.Christopher Missling already announced that he will reach the uplisting in a fast way.
The company is located in New York and isnt it so, that there will be in Octobre an international conference about this theme in New York - so just around the corner?
I just tried to find the information - but cant find it now in a hurry - have to search it again.
But that event would be a good date to show new results - and if the PPS is already above 3 Dollar till then and a uplisting is done too, then .... oh oh.
I think the time-window to get in with low prices will become smaller and smaller every day - i dont want to get catched like some people at OMER - this is an example what can happen when u are outside and the news comes. (even if its lower again it was a 77 % rise that day)
P.S.: The spread to buy Anavex is high for me - around 10 % - but i have now all i want - so it doesnt bother me anymore.
Hard to get Anavex shares as a European
And here is why:
I think it was June or July when Anavex got my attention while i was searching for new promising companies. And so i put it my watchlist after done some DD. I noticed a raising PPS and also an impressive raise in volume and decided to get my first position. The only tradeplace to get these OTC-shares was USA and so i choosed this - but it got cancelled by the system immediatly again.
A phonecall with my boker gave me clarification:
Low valuation OTC-stocks are not allowed anymore to buy. There has been some change in rules 1 year before, that i wasnt aware as i didnt trade some of them in that time. I looked for other marketplaces but there were none.
And so i watched the pps rising while i couldnt get in - till - that day i checked again the available marketplaces to see there that was a price shown in Berlin and there had been already happening some (very few) trades starting in begin of August.
So i got some dry powder and placed a buy order - but there was no ask.
After phonecalling the chief of the Berlin marketplace he promosed me to talk to the broker and soon a ask appears and i got my first shares....and was happy about it.
The spread is high and u never know is there a ask or not - but i wanted to increase my position.
I raised my stack during the last week and had to call the marketplace again for the same reason.
This whole procedure makes me think about:
What is with all the other european investors which still have no possibility to buy Anavex shares right now? I mean as a german investor i found the opportunity to buy them by coincidence.
So a french investor or someone from Belgium or the Netherlands - even if they want to buy - do they have a maketplace ?
How much does these missing buyers impact the current PPS?
There is missing a part of buying-pressure for sure - but how much will it be in PPS?
And there we come to the next point:
As far as i know there are also same restrictions for some of the guys with the deep pockets even in the US - they are not allowed to buy OTC - even if they want - and i am sure some of them have already their eyes on Anavex very closely.
This all will change after Anavex got uplisted.
Then here in Germany the bigger marketplaces like Franfurt and Stuttgart - even Munich will start trade the shares too and also direct buy in US is possible. I expect same changes in the other european countries. Then the buyers will come - and that will be a lot.
So the uplisting is a major change - what do we need for uplisting?
To my knowledge an OTC-stock must be minimum at 3 Dollar for some time - maybee i am wrong but thats what i know (maybee someone can verify this?)
Some more terms must be fullfilled but i think they have that all already.
A 3 Dollar PPS with an uplisting will change this stock dramatically.
The deep-pocket guys with OTC-restrictions will drive up the share price fast - and will dry up the available shares a lot.
How much institutional investors with 4,99 % (around 8 million shares from 160 million rounded) we have already? And how much are sitting and waiting on the sidelines to get their 4,99 % stack too - as soon as this is not OTC anymore?.
And so we reach the next point:
Isnt it so that also there are a lot institutional investors which have also a restriction to not buy a stock below a PPS of 5 Dollar?
So my conclusion is: with reaching a PPS of 3 Dollars the firewoks begins and a second boost comes after 5 Dollars.
That was the reason to make every effort to get my shares and to get them now and hold them tight!
We retail investors have here a very rare opportunity to get a part of a company which has a bright future - and we have it only now for a incredible low price!
Only 1 more good news like the anticipated confirmation of the first tremendous positive results will heave this stock far over 3 - even 5 Dollars and fulfill all terms for the big guys to buy all whats left and i am sure they are already in start position for that.
As english is not my first language and school is decades ago - i did my very best to express my thoughts here and hope all is understandable.
Feel free to copy this to the yahoo-board if u want to have there one more opinion to dodge the shorties - i am not a member there.
Thank you for your time reading this and good luck with all your investments.